H. Wilkins
Consultor / Asesor en Trialspark, Inc. .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Paul Sekhri | M | 65 |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.
Trialspark, Inc.
 Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 5 años |
| Todd Smith | M | 55 | 5 años | |
| Benjamine Liu | M | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 10 años |
| Linhao Zhang | M | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 10 años |
| Melissa Enbar | F | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 4 años |
| Steven Holtzman | M | 70 |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 3 años |
| Wendy Johnson | F | 72 |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | - |
| Jorge Ramírez | M | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 3 años |
| Gavin R. Corcoran | M | 61 |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 3 años |
| James Leslie | M | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 3 años |
| Emma Nealon | F | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 1 años |
| Roman Lesko | M | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 1 años |
| Ricardo Dolmetsch | M | 55 |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | - |
| Sabrina Comic Savic | F | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 4 años |
| Somberg Ken | M | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | - |
| Xiaoqi Liu | M | - |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | 1 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Robert Radie | M | 60 | 7 años | |
| Stephen Tullman | M | 58 |
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 años |
| Kamil Ali-Jackson | F | 65 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 años |
| Gary Phillips | M | 58 | 1 años | |
| Gregory Weaver | M | 68 | 6 años | |
| Alex Howarth | M | 55 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 años |
| Doug Gessl | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Robert Alonso | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 9 años |
| Timothy J. Henkel | M | 65 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Lisa Wittmer | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Jim Dowell | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Kevin Peacock | M | - |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 años |
| Bruce Goldsmith | M | 58 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 6 años |
| Kelly A. Copeland | F | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Jeffrey S. Shaver | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Martin Stogniew | M | 69 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| Evan G. Dick | M | 72 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 años |
| Tim Mayleben | M | 63 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | - |
| Pablo Cagnoni | M | 60 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | - |
| Luke Düster | M | 49 | - |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 36 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- H. Wilkins
- Red Personal
